Category: Licensing

Compulsory Licensing in South Africa

South Africa welcomes the opportunity to make submissions on the topic of exceptions and limitations. South Africa recognizes the role that Intellectual Property (IP) and Intellectual Property Rights (IPRs) play in the global context of advancing innovation, the dissemination of knowledge, the creation of thriving industries and its contribution to the global economy. It is … Continue reading Compulsory Licensing in South Africa

Read more »

Licensing in the UAE

The Federal Law of the UAE No. 17 of 2002, in the Regulation and protection of industrial property for patents and industrial designs in Article 1 clearly depicts the intent of the invention for which the patent is granted and indicated the same article specifies what is meant by a patent. It is clear that … Continue reading Licensing in the UAE

Read more »

Musical Work Used Commercially And Its Licensing Requirements

You cannot play music for your employees or the public in an office or shop or any commercial spaces, no matter what the medium is (phone system, radio, and disc, TV, or Bluetooth speakers). Business organizations or Entities that are interested in having singers sing or perform in their premises for any purpose need to … Continue reading Musical Work Used Commercially And Its Licensing Requirements

Read more »

A Brief Analysis Of Compulsory Licensing Pertinent To Copyright Law

Introduction As the title suggests, this particular blog deals with the compulsory licensing of copyright in our country. However, in order to understand compulsory licensing, the concept pertinent to “licenses” needs to be grasped first. Licenses are of two categories: one being voluntary license and the other being compulsory license. Section 30 of the Copyright … Continue reading A Brief Analysis Of Compulsory Licensing Pertinent To Copyright Law

Read more »

Zooming Out On Compulsory Licensing Of Covid-19 Vaccines

The unnerving bio- catastrophe, the COVID-19 pandemic has brought an array of challenges for mankind. The COVID-19 scare at the global level is posing threat to human life and the governments are deeply divided over an effort to endorse a temporary patent waiver on COVID-19 vaccines and grant of compulsory licenses. What is Compulsory Licensing? … Continue reading Zooming Out On Compulsory Licensing Of Covid-19 Vaccines

Read more »

Sisvel and Mitsubishi, and Xiaomi sign patent licensing deal to settle ongoing litigations

Recently, Sisvel and Mitsubishi jointly announced that the companies have entered into a patent license agreement covering the standard-essential patents (SEP) of Mitsubishi Electric and Sisvel in the field of mobile communication. This deal brings to an end the global dispute between the three companies, which has spanned the courts in China, Germany, Italy, the … Continue reading Sisvel and Mitsubishi, and Xiaomi sign patent licensing deal to settle ongoing litigations

Read more »

DelSiTech and Visus Therapeutics enter into Patent Licensing Arrangement

Recently, DelSiTech Ltd. (“DelSiTech”), a Finland-based drug delivery company entered into a patent licensing agreement over DelSiTech’s patents with Visus Therapeutics (“Visius”), a US-based company. This is a worldwide exclusive licensing agreement. Both companies are working on six development programs for eye care solutions targeting the management of ocular diseases of the back and front … Continue reading DelSiTech and Visus Therapeutics enter into Patent Licensing Arrangement

Read more »

ERS Genomics Licenses CRISPR-Cas9 patent and technology to Cellular Engineering Technologies

Recently, Dublin, Ireland-based biotechnology company, ERS Genomics Limited (“ERS”), has signed a nonexclusive license agreement with Iowa-based Cellular Engineering Technologies (“CET”) to grant access to its CRISPR-Cas9 patent portfolio. The financial terms of the agreement were not disclosed. ERS was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property for use as a … Continue reading ERS Genomics Licenses CRISPR-Cas9 patent and technology to Cellular Engineering Technologies

Read more »

Sun Pharma and Celegene Settle Patent Dispute over Lenalidomide (Revlimid®)

Settling an over three old patent infringement dispute, Indian pharmaceutical major, Sun Pharmaceuticals and its subsidiary, including US subsidiary (“Sun”), has reached a settlement with Celgene Corporation (“Celgene”), a subsidiary of pharmaceutical major Bristol Myers Squibb (BMS), to resolve and settle the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a … Continue reading Sun Pharma and Celegene Settle Patent Dispute over Lenalidomide (Revlimid®)

Read more »

Bajaj Healthcare Files Compulsory License with Indian Patent Office for Baricitinib

Recently, drug manufacturer, Bajaj Healthcare Limited issued a press release stating that they have filed a compulsory license application with the Indian Patent Office seeking permission to manufacture both active pharmaceutical ingredients (raw materials) and formulation of Baricitinib under the Indian Patents Act. Baricitinib is essentially a drug approved in the US and European Union, … Continue reading Bajaj Healthcare Files Compulsory License with Indian Patent Office for Baricitinib

Read more »

Archives

  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010